A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

H. S. Walter , S. A. Rule , M. J. S. Dyer , L. Karlin (1) , C. Jones , B. Cazin , Philippe Quittet (2, 3) , N. Shah , C. V. Hutchinson , H. Honda , K. Duffy , J. Birkett , V. Jamieson , N. Courtenay-Luck , T. Yoshizawa , J. Sharpe , T. Ohno , S. Abe , A. Nishimura , Guillaume Cartron (2, 3) , F. Morschhauser , C. Fegan , Gilles Salles (4, 5)

1 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
2 DIMNP - Dynamique des interactions membranaires normales et pathologiques
3 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
4 Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
5 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon

Mots clés: toxicity; therapeutic use; 80 and over; therapy; Adult; adverse effects; B-Cell; Chronic; B-Lymphocytes; Diffuse; Cohort Studies; blood; Diarrhea; drug effects; drug therapy; Female; Imidazoles; France; Hematoma; Hematology; Humans; Large B-Cell; Local; Leukemia; London; Lymphocytic; Male; Mantle-Cell; pathology; Neoplasm Recurrence; Lymphoma; Medicine; Patients; Pyrimidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; antagonists & inhibitors; Aged; Middle Aged

Domaines: Cancer

H. S. Walter, S. A. Rule, M. J. S. Dyer, L. Karlin, C. Jones, et al.. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood, 2016, 127 (4), pp.411-419. ⟨10.1182/blood-2015-08-664086⟩. ⟨hal-01796198⟩